We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-0.06%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.32B
AUM Growth
+$35.6M
Cap. Flow
+$88.2M
Cap. Flow %
6.66%
Top 10 Hldgs %
68.37%
Holding
46
New
2
Increased
28
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.2M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$31.9M
4
CEMP
Cempra, Inc.
CEMP
+$27.7M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$23M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$119M
2
ABMD
Abiomed Inc
ABMD
+$25.8M
3
MDVN
MEDIVATION, INC.
MDVN
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
DELISTED
Sage Therapeutics
SAGE
$12.6M 0.95%
+417,878
New +$13.9M
RIGL icon
27
Rigel Pharmaceuticals
RIGL
$782M
$12M 0.91%
538,653
+15,561
+3% +$387K
SQNM
28
DELISTED
SEQUENOM INC NEW
SQNM
$9.43M 0.71%
10,322,377
+298,535
+3% +$356K
EXAS
29
DELISTED
Exact Sciences
EXAS
$4.85M 0.37%
396,276
– –
TLPH icon
30
Talphera
TLPH
$72.7M
$3.83M 0.29%
71,272
– –
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.82M 0.29%
33,214
– –
ALIM
32
DELISTED
Alimera Sciences
ALIM
$3.71M 0.28%
200,920
– –
AIMT
33
DELISTED
Aimmune Therapeutics
AIMT
$3.52M 0.27%
325,599
– –
ALGN icon
34
Align Technology
ALGN
$12.4B
$2.93M 0.22%
36,357
+8,600
+31% +$658K
ACGN
35
DELISTED
Aceragen Inc
ACGN
$1.92M 0.15%
9,257
– –
ARCT icon
36
Arcturus Therapeutics
ARCT
$216M
$1.23M 0.09%
38,970
+2,657
+7% +$83.7K
CYTK icon
37
Cytokinetics
CYTK
$10.5B
$1.17M 0.09%
123,686
– –
PGEN icon
38
Precigen
PGEN
$2.45B
$1.16M 0.09%
47,524
– –
SPHS
39
DELISTED
Sophiris Bio, Inc.
SPHS
$1.06M 0.08%
494,000
– –
DRNA
40
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$804K 0.06%
267,890
– –
OCGN icon
41
Ocugen
OCGN
$475M
$777K 0.06%
7,576
– –
OREX
42
DELISTED
Orexigen Therapeutics, Inc.
OREX
$719K 0.05%
167,302
– –
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$237K 0.02%
29,500
+900
+3% +$8.78K
QURE icon
44
uniQure
QURE
$3.13B
$151K 0.01%
20,453
– –
MRNS
45
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$81K 0.01%
15,879
+1,125
+8% +$20.7K
ANAC
46
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-2,219,042
Closed -$119M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2016 Portfolio in Review

As of Q2 2016, Palo Alto Investors held 46 positions worth $1.32B, up 2.8% from $1.29B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Palo Alto Investors deployed $88.2M of net new capital in Q2 2016, opening 2 new positions and adding to 28 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 339,400 shares worth $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Abiomed Inc, an estimated $25.8M trimmed.

  • Palo Alto Investors's largest Q2 2016 buy was Alexion Pharmaceuticals: 339,400 shares worth $39.6M.
  • Palo Alto Investors added most to BioMarin Pharmaceuticals in Q2 2016, an estimated $33.8M increase.
  • Palo Alto Investors's biggest Q2 2016 reduction was Abiomed Inc, cutting an estimated $25.8M.
  • Palo Alto Investors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $119M.
  • Palo Alto Investors's ten largest holdings make up 68% of its $1.32B portfolio in Q2 2016.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q2 2016.
  • Palo Alto Investors's portfolio value rose 2.8% quarter-over-quarter to $1.32B.

Based on Palo Alto Investors's 13F filing for Q2 2016, filed 15 Aug 2016.